Chronic and Acute Pain Pipeline

DelveInsight’s, “Chronic and Acute Pain - Pipeline Insight, 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Chronic and Acute Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Chronic and Acute Pain: Understanding

Chronic and Acute Pain: Overview

Pain is a nearly universal experience that plays a critical role in health and disease, broadly classified as acute or chronic based on duration and cause. Acute pain is typically sudden in onset, short in duration (usually under 30 days), and arises from injury, surgery, or infection. It serves a protective function by signaling harm and promoting healing behaviors. Common in emergency and primary care, acute pain generally resolves as the underlying cause heals. Despite its short-term nature, it significantly contributes to lost productivity and healthcare use, being a leading cause of clinical visits and work absences. Chronic pain, in contrast, persists beyond normal healing—usually longer than 3 to 6 months—and may arise from past injury, illness, or no identifiable cause. Unlike acute pain, it often lacks a biological purpose and can severely impact mental, emotional, and social well-being. Conditions like fibromyalgia, arthritis, and neuropathic pain exemplify chronic pain, which commonly coexists with depression, anxiety, and sleep disturbances. Effective treatment requires a holistic, multidisciplinary approach that goes beyond reducing pain to improving overall function and quality of life. Chronic pain remains a major public health challenge with immense personal and economic costs.

 

Acute and chronic pain differ notably in their characteristics and impact. Acute pain is sudden, sharp, and localized, often linked to injury, surgery, or infection, and usually resolves as healing occurs. It activates the sympathetic nervous system, leading to physical signs like sweating or increased heart rate. Chronic pain, lasting over three months, is often dull, burning, or tingling, and may lack a clear cause. It commonly results from conditions like arthritis or nerve damage and significantly affects emotional health, often requiring comprehensive, long-term management.

 

Acute pain is typically diagnosed through patient history, physical examination, and tools like the Numeric Rating Scale (NRS) or Visual Analog Scale (VAS), sometimes supported by molecular biomarkers reflecting physiological changes. Quantitative Sensory Testing (QST) can help identify pain types and underlying mechanisms. For chronic pain, diagnosis focuses on ruling out treatable conditions and relies heavily on patient self-reports to assess pain's nature and effects. QST is also useful in differentiating between neuropathic and inflammatory pain. Advanced imaging methods like fMRI and PET, along with composite biomarkers, enhance personalized assessment by revealing nervous system and psychosocial changes.

 

Acute pain is primarily treated with non-opioid medications such as NSAIDs and acetaminophen, while opioids are used sparingly due to addiction risks. Multimodal analgesia is preferred to enhance relief and minimize opioid use, and newer drugs like suzetrigine show promise with fewer side effects. Non-drug approaches, including physical therapy and nerve stimulation, may also be effective. Chronic pain management takes a multidisciplinary approach, combining medications, psychological support, and interventions. First-line treatments include non-opioid drugs like SNRIs, TCAs, and topical agents, with opioids reserved for resistant cases and therapies like CBT and spinal cord stimulation addressing broader pain impacts.

 

"Chronic and Acute Pain- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic and Acute Pain pipeline landscape is provided which includes the disease overview and Chronic and Acute Pain treatment guidelines. The assessment part of the report embraces, in depth Chronic and Acute Pain commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic and Acute Pain collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Chronic and Acute Pain R&D. The therapies under development are focused on novel approaches to treat/improve Chronic and Acute Pain.

 

Chronic and Acute Pain Emerging Drugs Chapters

This segment of the Chronic and Acute Pain report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Chronic and Acute Pain Emerging Drugs

VER-01: Vertanical

VER‑01 is an investigational, standardized full-spectrum extract derived from the Cannabis sativa strain DKJ127 L, developed by Vertanical for the treatment of chronic pain. Its unique phytochemical composition includes cannabinoids such as cannabigerol, and terpenes like β-caryophyllene and α-bisabolol, which act synergistically through the entourage effect. The formulation is produced via a proprietary extraction process that preserves the full spectrum of the plant’s bioactive compounds. The drug is currently in Preregistration Phase for the treatment of Chronic Low Back Pain.

 

YZJ-4729: Shanghai Haiyan Pharmaceutical Technology Co., Ltd.

YZJ-4729 is an investigational drug being developed as a novel G protein-biased μ-opioid receptor (MOR) agonist for the management of severe acute pain requiring intravenous opioid therapy. Its significance lies in its mechanism of action, which is designed to selectively activate the analgesic G protein signaling pathway of the MOR while exhibiting minimal recruitment of β-arrestin-2, a process thought to be linked to undesirable side effects of traditional opioids like respiratory depression and gastrointestinal dysfunction. Currently, the drug is in Phase III for the treatment of postoperative acute pain.

 

PF614: Ensysce Biosciences

PF614 is an investigational oral extended-release oxycodone prodrug, designed for the management of moderate to severe acute postoperative pain. It utilizes Trypsin-Activated Abuse Protection (TAAP™) technology, PF614 aims to provide effective analgesia while reducing the potential for abuse and overdose associated with traditional opioids. PF614's formulation is designed to release oxycodone in a controlled manner, aiming to balance potent analgesic effects with a reduced risk of abuse. Currently, the drug is in Phase III for the treatment of acute postoperative pain.

 

ALLOD-2: Allodynic Therapeutics

ALLOD‑2 is an investigational oral fixed‑dose combination of naltrexone and acetaminophen, repurposed at lower doses. It is being developed to treat diverse pain conditions, including acute migraine, episodic migraine prevention, and chronic low back pain. Its mechanism includes dual blocking of innate immune activation (e.g. via TLR‑4 antagonism) and suppression of proinflammatory mediators such as TNF‑α, NO, ROS, alongside inhibition of COX‑2‑mediated pathways. ALLOD‑2 is currently in Phase II/III stage of its development for the treatment of migraine.

 

Dapansutrile: Olatec Therapeutics

Dapansutrile is an orally administered, small-molecule NLRP3 inflammasome inhibitor developed by Olatec Therapeutics for the treatment of acute gout flares and associated inflammatory pain. By selectively targeting the NLRP3 inflammasome, dapansutrile blocks the production of pro-inflammatory cytokines such as IL‑1β, which are key mediators of pain and swelling during gout attacks. This targeted mechanism offers a novel, non-steroidal and non-opioid approach to managing inflammatory pain. Dapansutrile is currently in Phase II/III stage of its development for the treatment of Acute Gout Flare.

 

LY3848575: Eli Lilly and Company

LY3848575 is an investigational monoclonal antibody developed by Eli Lilly and Company, designed for the treatment of chronic neuropathic pain. It works by targeting epiregulin, a protein involved in nerve signaling and pain pathways. By neutralizing epiregulin, LY3848575 aims to modulate abnormal neuronal activity, thereby reducing pain perception without engaging opioid pathways. The drug is administered via subcutaneous injection and is being developed as a monotherapy, offering a novel, non-opioid approach to managing neuropathic pain conditions. Its design as a monoclonal antibody allows for precise targeting of pathological pathways, with the potential for improved efficacy and safety in patients with chronic pain. Currently, the drug is in Phase II for the treatment of chronic pain.

 

RQ-00317076: RaQualia Pharma

RQ-00317076 is a small-molecule, selective COX-2 inhibitor being developed for the treatment of pain, including acute postoperative pain and chronic pain such as osteoarthritis. The compound has been developed to improve upon existing non-steroidal anti-inflammatory drugs (NSAIDs) by offering a different chemical structure than current COX-2 inhibitors.  Currently, the drug has completed Phase II for the treatment of acute postoperative pain and chronic pain.

 

CNTX-3001: Centrexion Therapeutics

CNTX‑3001 is a novel, non‑opioid small‑molecule therapeutic developed for intractable chronic lower back pain. It is administered intrathecally (via lumbar puncture) in a first‑in‑human Phase I trial to assess safety, pharmacokinetics, and preliminary efficacy. Designed for patients whose pain has been refractory to multiple prior therapies, the molecule aims to provide relief without the risks associated with systemic opioids. As a spinal‑targeted intervention, CNTX‑3001 offers a potentially durable analgesic option for difficult‑to‑treat moderate to severe low back pain. The drug is being developed with National Institutes of Health (NIH) as a partner. The drug is currently in Phase II stage of its development for the treatment of Lower Back Pain.

 Further product details are provided in the report……..

 

Chronic and Acute Pain: Therapeutic Assessment

This segment of the report provides insights about the different Chronic and Acute Pain drugs segregated based on following parameters that define the scope of the report, such as:

 

Major  Players in Chronic and Acute Pain

• There are approx. 180+ key companies which are developing the therapies for Chronic and Acute Pain. The companies which have their Chronic and Acute Pain drug candidates in the most advanced stage, i.e. Preregistration include, Vertanical.

 

Phases

DelveInsight’s report covers around 200+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Chronic and Acute Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

 

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Chronic and Acute Pain: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Chronic and Acute Pain therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic and Acute Pain drugs.

 

Chronic and Acute Pain Report Insights

• Chronic and Acute Pain Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Chronic and Acute Pain Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Chronic and Acute Pain drugs?
• How many Chronic and Acute Pain drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic and Acute Pain?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic and Acute Pain therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Chronic and Acute Pain and their status?
• What are the key designations that have been granted to the emerging drugs?